Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01657526
Registration number
NCT01657526
Ethics application status
Date submitted
2/08/2012
Date registered
6/08/2012
Date last updated
15/05/2017
Titles & IDs
Public title
Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine
Query!
Scientific title
An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Healthy Adults
Query!
Secondary ID [1]
0
0
116018
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Respiratory Disorders
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)
Other interventions - GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)
Other interventions - Saline placebo
Experimental: Group A - Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study
Placebo Comparator: Group B - Subjects in this group will receive placebo in Step 1 of the study
Experimental: Group C - Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study
Placebo Comparator: Group D - Subjects in this group will receive placebo in Step 2 of the study
Other interventions: GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)
Administered intramuscularly (IM) in the deltoid region of non-dominant arm
Other interventions: GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)
2 doses administered IM in the deltoid region of non-dominant arm
Other interventions: Saline placebo
2 doses administered IM in the deltoid region of non-dominant arm
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Occurrence of solicited local and general adverse event (AE), in all subjects, in all vaccine groups
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
During a 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after each vaccination.
Query!
Primary outcome [2]
0
0
Occurrence of any unsolicited AE, in all subjects, in all vaccine groups
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
During a 30-day follow-up period (i.e. day of vaccination and 29 subsequent days) after each vaccination.
Query!
Primary outcome [3]
0
0
Occurrence of haematological and biochemical laboratory abnormalities, in all subjects, in all vaccine groups
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
At baseline (Screening visit) and after each vaccination.
Query!
Primary outcome [4]
0
0
Occurrence of any serious adverse event (SAE), in all subjects, in all vaccine groups
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
From first vaccination to study conclusion (Day 420).
Query!
Primary outcome [5]
0
0
Occurrence of any potential Immune-Mediated Disease (pIMDs) in all subjects, in all vaccine groups
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
From first vaccination to study conclusion (Day 420).
Query!
Secondary outcome [1]
0
0
Humoral immune response to components of the NTHi vaccine formulations, in all subjects, in all vaccine groups
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Prior to each vaccination and 30 days post each vaccination.
Query!
Eligibility
Key inclusion criteria
- Subjects who, in the opinion of the investigator, can and will comply with the
requirements of the protocol.
- Written informed consent obtained from the subject.
- A male or female between, and including, 18 and 40 years of age at the time of the
first vaccination.
- Healthy subjects as established by medical history, physical examination and
laboratory assessment before entering into the study.
- Female subjects of non-childbearing potential may be enrolled in the study.
- Female subjects of childbearing potential may be enrolled in the study, if the
subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of vaccination, and
- has agreed to continue adequate contraception during the entire treatment period
and for 2 months after completion of the vaccination series.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
40
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Use of any investigational or non-registered product other than the study vaccines
within 30 days preceding the first dose of study vaccines, or planned use during the
study period.
- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational vaccine/product.
- Planned administration/administration of a vaccine/product not foreseen by the study
protocol in the period starting 30 days before the first vaccine dose and ending 30
days after the last dose of vaccines.
- Previous vaccination with a vaccine containing NTHi antigens.
- Chronic administration of immunosuppressants or other immune-modifying drugs within
six months prior to the first vaccine dose, or equivalent. Topical steroids are
allowed.
- Administration of immunoglobulins and/or any blood products within the 3 months
preceding the first dose of study vaccines or planned administration during the study
period.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
medical history and physical examination.
- Laboratory evidence of clinically significant haematological (complete blood cell
count [Red Blood Cells (RBC), White Blood Cells (WBC)], WBC differential count,
platelets count and haemoglobin level) and biochemical (Alanine Aminotransferase
[ALT], Aspartate Aminotransferase [AST], creatinine and lactate dehydrogenase [LDH])
abnormalities as per the opinion of the investigator based on the local laboratory
normative data.
- Acute disease and/or fever at the time of enrolment.
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
functional abnormality, as determined by physical examination or laboratory screening
tests.
- History of or current condition preventing intramuscular injection as bleeding or
coagulation disorder.
- Malignancies within previous 5 years (excluding non-melanic skin cancer) and
lymphoproliferative disorders.
- Pregnant or lactating female.
- Female planning to become pregnant or planning to discontinue contraceptive
precautions.
- History of chronic alcohol consumption and/or drug abuse.
- Any other condition that the investigator judges may interfere with study findings.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/08/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
25/11/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
48
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK
Biologicals' NTHi candidate vaccine in adults, administered for the first time in humans.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01657526
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01657526
Download to PDF